American Oriental up on OTC revenue
American Oriental Bioengineering, a Sino-US company producing and distributing drug and nutraceutical products throughout China, has announced a surge in earnings for the first quarter of 2008, driven by strong over-the-counter sales.
The firm reported net income of $9.4 million for the period ending March 31 2008. This was up 46% on the same quarter last year and gave the firm $0.12 earnings per diluted share. The results were driven by a 51% increase in revenue to $38.8 million.
Nutraceutical turnover for the company was down to $6.9 million during the quarter. This was more than made up for by a 72% increase in pharmaceuticals, accounting for $31.9 million of revenue. The highest contributing products were Shuanghuanglian Injection powder, Cease Enuresis Gel and the Jinji series of products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze